Search Results

Your search matched 13 results

#1

ICER Launches Their Next Generation of Cost Effectiveness Analyses | Blog

The Institute for Clinical and Economic Review (ICER) has gained industry-wide notoriety for their cost effectiveness analyses, which typically investigate the value of available treatments within a specific disease state.

#2

The Week That Was: Dude, where’s my paycheck? | Blog

What do CBD, digital health and “femtech” all have in common?

#3

The Week That Was: No one likes a bad kiss | Blog

Drug makers aren’t the only ones under pressure for high costs.

#4

The Week That Was: That LaLa feeling | Blog

Do you love that LaLa feeling?

#5

The Week That Was: We only ride in style | Blog

Employers wield enormous influence in deciding the care their employees receive – yet they aren’t always considered a core “stakeholder” in the healthcare debate.

#6

The Week That Was: You’ve GOAT to be kidding me | Blog

Everyone seems to be talking about digital health, but what does that really look like in action?

#7

The Week That Was: Ready, Set, Bird Box Challenge | Blog

In case you haven’t heard, it’s the New Year.

#8

The Week That Was: Put Your Font to Work | Blog

You may have seen a lot of recent reporting on “loss of coverage” for Americans.

#9

The Week That Was: Nowhere Left To Go | Blog

There’s a lot to be learned from Boeing’s reputational challenges – and their early efforts to start rebuilding trust among pilots, flight attendants and customers.

#10

The Week That Was: Thank u, next | Blog

The anti-vaccination movement is causing challenges not just in healthcare, but now in tech.

#11

The Week That Was: Smile like You Mean It | Blog

As the industry awaits a potential executive order on transparency around healthcare costs, we took a look at some transparency tools, and where they’re falling short.

#12

The Week That Was: May We Borrow $52m? | Blog

AI is to 2019 what blockchain was to 2018.

#13

The Week That Was: Bye-bye midtown uniform | Blog

Prescription delivery services – like Hims, Roman and Kick – are popping up all over the place, prompting concerns about regulation.